biotech

Exit Opportunities for Biotech Investors: US vs Europe

Filed in archive Corporate and Industrial News on August 30, 2005

BlogPicture

In an article published recently in Nature's Bioentrepreneur, a comparison of initial public offerings (IPOs) and trade sale exits through mergers and acquisitions (M&A) seems to suggest that biotech prospects are shifting to Europe.
... second-quarter European biotech IPO volume was the strongest it's been since 2000. All told, in the first half of 2005, European IPO proceeds actually topped those in the US, reaching nearly $500 million, debunking yet another myth about relative exit opportunities across the Atlantic. In fact, the average value of biotech IPOs in Europe is rising. This year the average proceeds hit $40 million, more than twice what they were just two years ago. By comparison, biotech proceeds in the US have remained level at around $60 million.


Read the full article here.

Permalink: Exit Opportunities for Biotech Investors: US vs Europe

Tags: biotech  IPO  europe  exit  opportunities  exit+opportunities  biotech+investors  investors+europe 

Vote for Exit Opportunities for Biotech Investors: US vs Europe:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 1 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells